Voyager Therapeutics, Inc.
VYGR
$3.47
-$0.06-1.70%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 80.00M | 163.78M | 143.77M | 119.04M | 250.01M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 80.00M | 163.78M | 143.77M | 119.04M | 250.01M |
| Cost of Revenue | 127.37M | 117.54M | 113.16M | 100.70M | 92.17M |
| Gross Profit | -47.37M | 46.24M | 30.61M | 18.35M | 157.84M |
| SG&A Expenses | 35.92M | 37.17M | 37.26M | 35.40M | 35.82M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 163.29M | 154.71M | 150.42M | 136.10M | 127.99M |
| Operating Income | -83.29M | 9.08M | -6.65M | -17.05M | 122.01M |
| Income Before Tax | -64.34M | 26.78M | 9.71M | -2.33M | 133.74M |
| Income Tax Expenses | 665.00K | 903.00K | 683.00K | 718.00K | 1.41M |
| Earnings from Continuing Operations | -65.00 | 25.88 | 9.02 | -3.04 | 132.33 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -65.00M | 25.88M | 9.02M | -3.04M | 132.33M |
| EBIT | -83.29M | 9.08M | -6.65M | -17.05M | 122.01M |
| EBITDA | -78.56M | 14.13M | -1.78M | -12.49M | 126.46M |
| EPS Basic | -1.13 | 0.75 | 0.32 | -0.02 | 3.23 |
| Normalized Basic EPS | -0.70 | 0.48 | 0.21 | 0.00 | 2.04 |
| EPS Diluted | -1.14 | 0.71 | 0.28 | -0.05 | 3.09 |
| Normalized Diluted EPS | -0.70 | 0.46 | 0.19 | -0.02 | 1.95 |
| Average Basic Shares Outstanding | 230.66M | 216.67M | 202.69M | 188.49M | 172.00M |
| Average Diluted Shares Outstanding | 230.66M | 217.77M | 203.78M | 189.58M | 174.62M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |